肺神经内分泌肿瘤中的程序性死亡受体配体1（PD-L1）表达
PD-L1 expression in neuroendocrine tumors of the lung.
作者信息
Tsuruoka Kenjiro, Horinouchi Hidehito, Goto Yasushi, Kanda Shintaro, Fujiwara Yutaka, Nokihara Hiroshi, Yamamoto Noboru, Asakura Keisuke, Nakagawa Kazuo, Sakurai Hiroyuki, Watanabe Shun-Ichi, Tsuta Koji, Ohe Yuichiro
机构信息
Department of Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan.
Department of Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo 104-0045, Japan.
出版信息
Lung Cancer. 2017 Jun;108:115-120. doi: 10.1016/j.lungcan.2017.03.006. Epub 2017 Mar 24.
BACKGROUND
Various tumors express programmed cell death ligand 1 (PD-L1), an immune checkpoint ligand, the expression of which correlates with certain effects of anti-programmed cell death 1 (PD-1)/PD-L1 drugs. The aim of this study was to assess the frequency of PD-L1 expression in each of the types of neuroendocrine tumors of the lung.
METHODS
The subjects enrolled in this study were patients who had been diagnosed with neuroendocrine tumors of the lung and had been treated at the National Cancer Center Hospital (Tokyo, Japan) between 1982 and 2010. We performed immunohistochemical analysis on a tissue microarray (TMA) of the surgical specimens using the validated PD-L1 antibody clone, E1L3N. Tumor PD-L1 expression scores were calculated semiquantitatively (staining intensity [0-3]×stained area [0-100%]). A score of 1 was used as a cut-off to determine the presence or absence of PD-L1 expression.
RESULTS
Among the 227 patients included in this study, the patient demographics were as follows: median age (range), 65 years (19-84); sex (male/female), 168/59; pStage (IA, IB, IIA, IIB, IIIA, IIIB, IV): 79, 36, 25, 29, 47, 6, 5, respectively; and histology was typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC), small cell lung cancer (SCLC): 46, 6, 106, 69, respectively. The numbers (proportions) of PD-L1-expression tumors were as follows: TC/AC/LCNEC/SCLC, 0/0/11 (10.4%)/4 (5.8%).
CONCLUSIONS
PD-L1 expression was apparent in 10.4% of LCNEC and 5.8% of SCLC tumors, and was not observed in carcinoid tumors.
背景
多种肿瘤表达程序性细胞死亡配体1（PD-L1），这是一种免疫检查点配体，其表达与抗程序性细胞死亡1（PD-1）/PD-L1药物的某些效应相关。本研究的目的是评估肺神经内分泌肿瘤各类型中PD-L1表达的频率。
方法
本研究纳入的受试者为1982年至2010年间在日本东京国立癌症中心医院被诊断为肺神经内分泌肿瘤并接受治疗的患者。我们使用经过验证的PD-L1抗体克隆E1L3N对手术标本的组织微阵列（TMA）进行免疫组织化学分析。肿瘤PD-L1表达评分采用半定量计算（染色强度[0-3]×染色面积[0-100%]）。以1分为临界值来确定PD-L1表达的有无。
结果
本研究纳入的227例患者中，患者人口统计学特征如下：年龄中位数（范围）为65岁（19-84岁）；性别（男/女）为168/59；病理分期（IA、IB、IIA、IIB、IIIA、IIIB、IV期）分别为79、36、25、29、47、6、5例；组织学类型为典型类癌（TC）、非典型类癌（AC）、大细胞神经内分泌癌（LCNEC）、小细胞肺癌（SCLC）的分别为46、6、106、69例。PD-L1表达肿瘤的数量（比例）如下：TC/AC/LCNEC/SCLC分别为0/0/11例（10.4%）/4例（5.8%）。
结论
10.4%的LCNEC肿瘤和5.8%的SCLC肿瘤中可见PD-L1表达，类癌肿瘤中未观察到PD-L1表达。
Zotero 插件